Clinical Report: The Role of 10-Formyltetrahydrofolate Dehydrogenase Expression in Hormone Receptor-Positive Breast Cancer

Overview

This study investigates the expression of ALDH1L1 in breast cancer, revealing that higher levels are associated with better survival outcomes, particularly in hormone receptor-positive subtypes. The findings suggest ALDH1L1 as a potential biomarker and therapeutic target in breast cancer management.

Background

Breast cancer remains a leading cause of cancer-related mortality among women, necessitating the identification of effective biomarkers for risk stratification and treatment. ALDH1L1 has been implicated in tumor suppression, yet its clinical significance in breast cancer, especially in hormone receptor-positive subtypes, has not been fully elucidated. Understanding the role of ALDH1L1 could enhance therapeutic strategies and patient outcomes.

Data Highlights

Key Findings

• ALDH1L1 expression is higher in non-tumor tissues compared to cancer tissues.
• Increased ALDH1L1 expression correlates with smaller tumor size and lower pT stage in luminal A and HER2+ subtypes.
• Higher ALDH1L1 levels are linked to improved overall and disease-free survival in hormone receptor-positive breast cancer.
• ALDH1L1 expression inversely correlates with advanced tumor stage and lymphatic spread.
• Proliferation assays indicate cytotoxic effects of ALDH1L1 in luminal breast cancer cell lines.

Clinical Implications

The findings suggest that ALDH1L1 could serve as a favorable biomarker for prognosis in hormone receptor-positive breast cancer, potentially guiding treatment decisions. Clinicians may consider monitoring ALDH1L1 expression levels to better stratify patients and tailor therapeutic approaches.

Conclusion

ALDH1L1 expression is a promising biomarker associated with better clinical outcomes in hormone receptor-positive breast cancer, highlighting its potential role in future therapeutic strategies.

Related Resources & Content

1. The ASCO Post, 2015 -- Complexities of Targeting HER2 in Estrogen Receptor–Positive Breast Cancers
2. The ASCO Post, 2015 -- Understanding the Role of Immune Function in the Treatment of HER2-Positive Breast Cancer
3. Journal of Clinical Oncology, 2024 -- Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
4. FDA -- FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
5. Nature Cancer -- Cycling back to folate metabolism in cancer
6. The ASCO Post — Complexities of Targeting HER2 in Estrogen Receptor–Positive Breast Cancers
7. The ASCO Post — ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer
8. Endocrine and Targeted Therapy for Hormone Receptor–Positive, HER2– Negative Metastatic Breast Cancer
9. ESMO Living Guidelines for HR+/HER2– Metastatic Breast Cancer
10. Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update | Journal of Clinical Oncology
11. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer | FDA
12. FDA expands early breast cancer indication for abemaciclib with endocrine therapy | FDA
13. Cycling back to folate metabolism in cancer | Nature Cancer
14. Frontiers | Clinical implications of 10-formyltetrahydrofolate dehydrogenase expression in hormone receptor-positive breast cancer